Similar articles

• [Leucovorin rescue after continuing infusion of high dose methotrexate].

  Yang LH, Lu XT, Gu J, Hua Y, Zhao WH. Yang LH, et al. Zhonghua Er Ke Za Zhi. 2005 May;43(5):393-4. Zhonghua Er Ke Za Zhi. 2005. PMID: 15924763 Chinese. No abstract available.
• Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.

  Lange BJ, Blatt J, Sather HN, Meadows AT. Lange BJ, et al. Med Pediatr Oncol. 1996 Jul;27(1):15-20. doi: 10.1002/(SICI)1096-911X(199607)27:1<15::AID-MPO4>3.0.CO;2-X. Med Pediatr Oncol. 1996. PMID: 8614385 Clinical Trial.
• Intracellular pharmacology and biochemistry of methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia.

  Keuzenkamp-Jansen CW, Bökkerink JP, Trijbels JM, vd Heijden MA, De Abreu RA. Keuzenkamp-Jansen CW, et al. Adv Exp Med Biol. 1994;370:115-8. doi: 10.1007/978-1-4615-2584-4_26. Adv Exp Med Biol. 1994. PMID: 7660872 No abstract available.
• High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?

  Mantadakis E, Cole PD, Kamen BA. Mantadakis E, et al. Pharmacotherapy. 2005 May;25(5):748-55. doi: 10.1592/phco.25.5.748.63584. Pharmacotherapy. 2005. PMID: 15899736 Review.
• [Accidental shortening time of high dose methotrexate infusion: case report and literature review].

  Charfi R, Salouage I, Trabelsi S, Zarrouk M, Gaïes E, Jebabli N, Meddeb B, Lakhal M, Klouz A. Charfi R, et al. Ann Biol Clin (Paris). 2013 Mar-Apr;71(2):219-22. doi: 10.1684/abc.2013.0803. Ann Biol Clin (Paris). 2013. PMID: 23587592 Review. French.